Ideaya Biosciences Inc (NASDAQ:IDYA) price on Friday, June 13, fall -0.45% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $22.18.
A look at the stock’s price movement, the close in the last trading session was $22.28. Turning to its 52-week performance, $44.42 and $13.45 were the 52-week high and 52-week low respectively. Overall, IDYA moved 29.71% over the past month.
Ideaya Biosciences Inc’s market cap currently stands at around $1.94 billion, with investors looking forward to this quarter’s earnings report slated for in July.
Wall Street analysts have also projected the company’s year-on-year revenue to grow to 14.15M, representing a 102.21% jump on that reported in the last financial year.
11 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 10 recommend IDYA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
IDYA’s current price about 8.56% and 17.89% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 64.19, while 7-day volatility ratio is 3.11% and 2.98% in the 30-day chart. Further, Ideaya Biosciences Inc (IDYA) has a beta value of 0.03, and an average true range (ATR) of 1.09. Analysts have given the company’s stock an average 52-week price target of $51.5, forecast between a low of $18 and high of $66. Looking at the price targets, the low is 18.85% off current price level while to achieve the yearly target high, price needs to move -197.57%. Nonetheless, investors will most likely welcome a -132.19% jump to $51.5 which is the analysts’ median price.
If we refocus on Ideaya Biosciences Inc (NASDAQ:IDYA), historical trading data shows that trading volumes averaged 1.42 million over the past 3 months. The company’s latest data on shares outstanding shows there are 87.57 million shares.
The 10.05% of Ideaya Biosciences Inc’s shares are in the hands of company insiders while institutional holders own 106.24% of the company’s shares. Current price change has pushed the stock -13.70% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the IDYA stock continues to rise going into the next quarter.
